← Leaderboards
Sophie Paczesny
Medical University Of South Carolina
$15,189,813
Attributed
$21,386,256
Total exposure
14
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,386,256 · 14
By mechanism
R01$13,408,078 · 6
U01$4,282,428 · 1
RC1$999,999 · 1
P01$930,243 · 1
U54$682,133 · 1
R21$547,063 · 2
Top collaborators
- Chao-Yie Yang7 shared
- Jamie L Renbarger5 shared
- Brent R Logan4 shared
- Nai-Kong V Cheung3 shared
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- Mark P Rubinstein$2,818,767
- John M. Wrangle$2,019,783
- Besim Ogretmen$19,638,711
Others in their field
Top investigators on “Allogenic”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Mary M Horowitz · Medical College Of Wisconsin$47,632,939
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$40,815,122
- Marcel R M Van Den Brink · Sloan-Kettering Institute For Cancer Res$39,678,762
- Bruce R. Blazar · University Of Minnesota$37,193,531
- Megan Sykes · Columbia University Health Sciences$33,587,479
Research focus
AllogenicPlasmaBiological MarkersSamplingProteomicsHematopoietic Stem Cell TransplantationComplicationBaseAcute Graft Versus Host DiseaseMalignant - DescriptorSteroidsT-LymphocyteInnovationCurative TreatmentsProteinsBiologicalMortalityPathway InteractionsBloodReceptorRegimenValidationInsightHematopoietic Cell Transplantation
Grant awards (51)
Machine Learning to identify Biomarkers for Risk of Chronic Graft-Versus-Host Disease$693,916
R01 · FY2025 · CA · contact PI
IL-33 induced-lL-9 producing type 2 innate lymphoid cells in the regulation of acute lung injury after hematopoietic stem cell transplantation (HSCT) in pediatric patients$562,620
R01 · FY2025 · HL · contact PI
IL-33 induced-lL-9 producing type 2 innate lymphoid cells in the regulation of acute lung injury after hematopoietic stem cell transplantation (HSCT) in pediatric patients$551,368
R01 · FY2024 · HL · contact PI
Translating Novel Drug-Targetable Biomarkers to Treat Graft versus Host Disease$307,043
R01 · FY2024 · CA · contact PI
Machine Learning to identify Biomarkers for Risk of Chronic Graft-Versus-Host Disease$215,348
R01 · FY2024 · CA · contact PI
Chronic Graft-Versus-Host Disease Biomarkers: Prediction of Resistance to Therapy$188,750
R21 · FY2024 · AI · contact PI
Machine Learning to identify Biomarkers for Risk of Chronic Graft-Versus-Host Disease$596,367
R01 · FY2023 · CA · contact PI
IL-33 induced-lL-9 producing type 2 innate lymphoid cells in the regulation of acute lung injury after hematopoietic stem cell transplantation (HSCT) in pediatric patients$564,346
R01 · FY2023 · HL · contact PI
Translating Novel Drug-Targetable Biomarkers to Treat Graft versus Host Disease$317,179
R01 · FY2023 · CA · contact PI
Chronic Graft-Versus-Host Disease Biomarkers: Prediction of Resistance to Therapy$226,500
R21 · FY2023 · AI · contact PI
Cancer Immunology$43,932
P30 · FY2023 · CA · contact PI
Development of first-in-class ST2 inhibitors for treating graft-versus-host disease$633,696
R01 · FY2022 · HL
Machine Learning to identify Biomarkers for Risk of Chronic Graft-Versus-Host Disease$628,188
R01 · FY2022 · CA · contact PI
IL-33 induced-lL-9 producing type 2 innate lymphoid cells in the regulation of acute lung injury after hematopoietic stem cell transplantation (HSCT) in pediatric patients$625,635
R01 · FY2022 · HL · contact PI
Translating Novel Drug-Targetable Biomarkers to Treat Graft versus Host Disease$317,472
R01 · FY2022 · CA · contact PI
Cancer Immunology$43,932
P30 · FY2022 · CA · contact PI
Development of first-in-class ST2 inhibitors for treating graft-versus-host disease$636,111
R01 · FY2021 · HL
Translating Novel Drug-Targetable Biomarkers to Treat Graft versus Host Disease$323,667
R01 · FY2021 · CA · contact PI
Cancer Immunology$43,932
P30 · FY2021 · CA · contact PI
Development of first-in-class ST2 inhibitors for treating graft-versus-host disease$650,311
R01 · FY2020 · HL
Translating Novel Drug-Targetable Biomarkers to Treat Graft versus Host Disease$345,428
R01 · FY2020 · CA · contact PI
Project 2: Biomarkers of endothelial dysfunction in pediatric patients receiving high intensity chemotherapy/irradiation$202,258
P50 · FY2020 · HD · contact PI
Dual targeting of tumoral microenvironment and tumoral cells by blocking the IL-33/ST2 pathway$153,053
U01 · FY2020 · CA · contact PI
Development of first-in-class ST2 inhibitors for treating graft-versus-host disease$641,835
R01 · FY2019 · HL
Project 2: Biomarkers of endothelial dysfunction in pediatric patients receiving high intensity chemotherapy/irradiation$202,258
P50 · FY2019 · HD · contact PI
Dual targeting of tumoral microenvironment and tumoral cells by blocking the IL-33/ST2 pathway$2,940,474
U01 · FY2018 · CA · contact PI
Dual targeting of tumoral microenvironment and tumoral cells by blocking the IL-33/ST2 pathway$1,188,901
U01 · FY2018 · CA · contact PI
Project 2: Biomarkers of endothelial dysfunction in pediatric patients receiving high intensity chemotherapy/irradiation$213,321
U54 · FY2018 · HD · contact PI
Bridging Pediatric and Adult Biomarkers of Graft-Versus-Host-Disease$491,398
R01 · FY2017 · HD · contact PI
Project 2: Biomarkers of endothelial dysfunction in pediatric patients receiving high intensity chemotherapy/irradiation$213,258
U54 · FY2017 · HD · contact PI
Biomarkers for risk of chronic Graft-Versus-Host Disease occurrence$131,813
R21 · FY2017 · HL · contact PI
Translating Novel Drug-Targetable Biomarkers to Treat Graft versus Host Disease$69,085
R01 · FY2017 · CA · contact PI
Bridging Pediatric and Adult Biomarkers of Graft-Versus-Host-Disease$505,765
R01 · FY2016 · HD · contact PI
Translating Novel Drug-Targetable Biomarkers to Treat Graft versus Host Disease$324,148
R01 · FY2016 · CA · contact PI
Project 2: Biomarkers of endothelial dysfunction in pediatric patients receiving high intensity chemotherapy/irradiation$255,554
U54 · FY2016 · HD · contact PI
Bridging Pediatric and Adult Biomarkers of Graft-Versus-Host-Disease$458,943
R01 · FY2015 · HD · contact PI
Translating Novel Drug-Targetable Biomarkers to Treat Graft versus Host Disease$325,553
R01 · FY2015 · CA · contact PI
High Throughput Screening (HTS) to Discover Graft-Versus-Host Disease Inhibitors$323,596
R01 · FY2015 · CA · contact PI
Bridging Pediatric and Adult Biomarkers of Graft-Versus-Host-Disease$454,296
R01 · FY2014 · HD · contact PI
Translating Novel Drug-Targetable Biomarkers to Treat Graft versus Host Disease$334,113
R01 · FY2014 · CA · contact PI
High Throughput Screening (HTS) to Discover Graft-Versus-Host Disease Inhibitors$313,891
R01 · FY2014 · CA · contact PI
Clinical Sample Database and Proteomics$177,805
P01 · FY2014 · CA · contact PI
Bridging Pediatric and Adult Biomarkers of Graft-Versus-Host-Disease$529,239
R01 · FY2013 · HD · contact PI
High Throughput Screening (HTS) to Discover Graft-Versus-Host Disease Inhibitors$337,559
R01 · FY2013 · CA · contact PI
Translating Novel Drug-Targetable Biomarkers to Treat Graft versus Host Disease$329,962
R01 · FY2013 · CA · contact PI
Clinical Sample Database and Proteomics$243,394
P01 · FY2013 · CA · contact PI
Clinical Sample Database and Proteomics$167,489
P01 · FY2012 · CA · contact PI
Clinical Sample Database and Proteomics$168,038
P01 · FY2011 · CA · contact PI
Graft versus Host Disease Biomarkers: Prediction of Onset and Response to Therapy$499,999
RC1 · FY2010 · HL · contact PI
Clinical Sample Database and Proteomics$173,517
P01 · FY2010 · CA · contact PI
Graft versus Host Disease Biomarkers: Prediction of Onset and Response to Therapy$500,000
RC1 · FY2009 · HL · contact PI